Adamas Pharmaceuticals, Inc. announced that on December 7, 2015, Jeffrey Knapp, Chief Operating Officer, resigned effective January 29, 2016, for personal reasons. John MacPhee, a member of board of directors, will provide commercial advisory oversight on an interim basis until a Chief Commercial Officer is named.
Adamas Pharmaceuticals, Inc.
Equities
ADMS
US00548A1060
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+33.35% | 49.46B | |
+1.76% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.81% | 26.61B | |
-22.30% | 18.64B | |
+7.83% | 13.16B | |
+29.52% | 12.55B | |
+24.25% | 12.1B |